EC approves Shire's Adynovi for hemophilia A

The European Commission approved Adynovi (BAX 855) from Shire plc (LSE:SHP; NASDAQ:SHPG) for on-demand and prophylactic use in hemophilia A patients ages 12 and older. The pegylated form of recombina...